MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Erasca Inc

Cerrado

1.38 -0.72

Resumen

Variación precio

24h

Actual

Mínimo

1.36

Máximo

1.38

Métricas clave

By Trading Economics

Ingresos

-1M

-32M

BPA

-0.11

Empleados

103

EBITDA

1.5M

-35M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+257.14% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-62M

351M

Apertura anterior

2.1

Cierre anterior

1.38

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Erasca Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 abr 2025, 17:01 UTC

Ganancias
Principales Movimientos del Mercado

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25 abr 2025, 16:10 UTC

Ganancias
Principales Movimientos del Mercado

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26 abr 2025, 18:14 UTC

Ganancias

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26 abr 2025, 15:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26 abr 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

25 abr 2025, 21:24 UTC

Principales Noticias

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25 abr 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

25 abr 2025, 20:45 UTC

Principales Noticias

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25 abr 2025, 20:39 UTC

Ganancias

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25 abr 2025, 20:37 UTC

Principales Noticias

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25 abr 2025, 20:19 UTC

Principales Noticias

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25 abr 2025, 20:15 UTC

Ganancias

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25 abr 2025, 19:23 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25 abr 2025, 19:18 UTC

Charlas de Mercado

Oil Futures End Choppy Week With Losses -- Market Talk

25 abr 2025, 18:47 UTC

Charlas de Mercado

Gold Extends Pullback to Close Week -- Market Talk

25 abr 2025, 18:39 UTC

Principales Noticias

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25 abr 2025, 18:34 UTC

Adquisiciones, fusiones, absorciones

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25 abr 2025, 18:32 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

25 abr 2025, 18:32 UTC

Charlas de Mercado
Ganancias

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25 abr 2025, 18:08 UTC

Ganancias

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25 abr 2025, 17:55 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25 abr 2025, 17:40 UTC

Principales Noticias

Consumers Continue to Sour on the Economy -- 4th Update

25 abr 2025, 17:38 UTC

Ganancias

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25 abr 2025, 17:07 UTC

Charlas de Mercado

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25 abr 2025, 16:54 UTC

Charlas de Mercado
Ganancias

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25 abr 2025, 16:46 UTC

Ganancias

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25 abr 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

25 abr 2025, 16:12 UTC

Principales Noticias

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25 abr 2025, 16:03 UTC

Ganancias

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 abr 2025, 15:52 UTC

Charlas de Mercado

Grains Mixed on Low Volume Trade -- Market Talk

Comparación entre iguales

Cambio de precio

Erasca Inc Esperado

Precio Objetivo

By TipRanks

257.14% repunte

Estimación a 12 meses

Media 5 USD  257.14%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Erasca Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.24 / 1.4Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.